Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Moody's
MCO
5
Jefferies Financial
JEF
HK Stock MarketDetailed Quotes
02607 SH PHARMA
- 10.640
- +0.020+0.19%
Market Closed May 2 16:08 CST
39.46BMarket Cap8.38P/E (TTM)
10.720High10.500Low2.06MVolume10.620Open10.620Pre Close21.79MTurnover0.22%Turnover Ratio8.02P/E (Static)3.71BShares14.70052wk High0.50P/B9.78BFloat Cap9.95352wk Low0.53Dividend TTM919.07MShs Float24.612Historical High0.440Dividend LFY2.07%Amplitude2.037Historical Low10.581Avg Price100Lot Size4.95%Div YieldTTM4.14%Div Yield LFY
About SH PHARMA Company
The company is a large pharmaceutical industry group listed in Shanghai and Hong Kong. The company advocates the core corporate values of “innovation, honesty, cooperation, tolerance and responsibility”, and is committed to persevere, improve people's healthy quality of life, and strive to become a leading brand drug manufacturer and health service provider that is respected and has a reputation in the industry. The company's main business is the pharmaceutical industry and pharmaceutical business. The company's main products: hydroxychloroquine sulfate tablets, injectable urastatin, gastric rejuvenation capsules, polysaccharide iron complex capsules, bifidobacteria trifecta active bacterial preparations. Corporate honors: “2023 Asia Pacific Quality Organization - Innovation Award”, the company won 27 national quality awards, 112 provincial and municipal quality awards, the “Fortune 500” list, and won the “Top 50 Global Pharmaceutical Companies”, “Top 25 Global Pharmaceutical Brands”, “China's Top 100 Pharmaceutical Industry Companies”, and “China's Top 100 Pharmaceutical Industry Companies”, and “Best Industrial Enterprise in China's Pharmaceutical R&D Product Line”, ranked 473rd among the 2020 Fortune Global 500, and is one of only two Chinese pharmaceutical companies; In “Fortune It ranked 57th in the 2020 Fortune China 500 published by “Fortune” (Chinese version); ranked 1009th in the 2020 Global Top 2000 Companies published by “Forbes”, and ranked 2nd in the overall strength of China Pharmaceutical Group.
Company Profile
Symbol02607
Company NameSH PHARMA
ISINCNE1000012B3
Listing DateMay 20, 2011
Issue Price23.00
Shares Offered664.21M share(s)
FoundedJan 18, 1994
Registered AddressChina
Chairmanqiuhua yang
Secretarytaohuangpeiqiao zhong
Audit InstitutionDeloitte Huayong Certified Public Accountants (Special General Partnership)
Company CategoryMainland registration of Mainland State-owned Assets control
Registered OfficeNo. 92, Zhangjiang Road, China (Shanghai) Pilot Free Trade Zone
Head Office and Principal Place of BusinessRoom 1918, 19th floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees49402
MarketHong Kong motherboard
Phone8621-63730908
Fax8621-63289333
Emailpharm@sphchina.com
Websitehttp://www.sphchina.com
BusinessPharmaceutical products of various dosage forms (including but not limited to tablets, capsules, aerosols, immunological preparations, granules, ointments, pills, oral solutions, inhalants, injections, liniments, tinctures, suppositories) (including but not limited to the development of chemical raw materials, chemical preparations, Chinese herbal medicines, proprietary Chinese medicines, Chinese herbal medicines, herbal medicines, biological products, narcotic drugs, psychotropic drugs, toxic drugs for medical use [appropriate to the scope of business], vaccines), health products, medical devices and related products Manufacturing and sales, pharmaceutical equipment manufacturing, sales and engineering installation, maintenance, warehousing and logistics, offshore , land and air freight forwarding business, industrial investment, asset management, provision of international economic and trade information and consulting services, leasing of own housing, and import and export business of various kinds of pharmaceuticals and related commodities and technology (the above involves licensed operations).
Company Executives
- Name
- Position
- Salary
- qiuhua yang
- Chairman, Executive Director, Chairman of the Strategy Committee, Remuneration Committee Member
- --
- bo shen
- President, Executive Director, Nomination Committee Members, Authorized Representative
- --
- yongzhong li
- Executive President, Executive Director
- --
- ming dong
- Executive Director
- --
- wenxue zhang
- Non-executive Directors, Strategy Committee Members
- --
- chaoyang gu
- Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Members, Nomination Committee Members
- --
- wenxun huo
- Independent Non-Executive Director, Chairman of the Nomination Committee, Audit Committee Members
- --
- zhong wang
- Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Member, Strategy Committee Member
- --
- jun wan
- Independent Non-Executive Director, Nomination Committee Members
- --
- youli xu
- Chief Supervisor
- --
- weidong yu
- Employee Representative Supervisor
- --
- jia ma
- Auditors
- --
- yong zhao
- VP
- --
- jianyi mao
- VP
- --
- yaohua zhang
- VP
- --
- tao zhong
- VP, Joint Company Secretary, Board Secretary, Authorized Representative
- --
- dongming li
- VP
- --
- maitiaili mai
- VP
- --
- shuai shao
- VP
- --
- peiqiao huang
- Joint Company Secretary, Legal Process Agent
- --
- yadong zhou
- VP, Chief Financial Officer
- --
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. Do you think Buffett was scooping up stocks during the recent dip? 2. In the face of market changes, do you prefer to stick
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts